Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted
Kurt Rasmussen, David A. White, Jane B. Acri
Neuropsychopharmacology (2018) Vol. 44, Iss. 4, pp. 657-659
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

The changing opioid crisis: development, challenges and opportunities
Nora D. Volkow, Carlos Blanco
Molecular Psychiatry (2020) Vol. 26, Iss. 1, pp. 218-233
Open Access | Times Cited: 317
Addiction as a brain disease revised: why it still matters, and the need for consilience
Markus Heilig, James MacKillop, Diana Martínez, et al.
Neuropsychopharmacology (2021) Vol. 46, Iss. 10, pp. 1715-1723
Open Access | Times Cited: 202
Structure-based discovery of nonopioid analgesics acting through the α 2A -adrenergic receptor
Elissa A. Fink, Jun Xu, Harald Hübner, et al.
Science (2022) Vol. 377, Iss. 6614
Open Access | Times Cited: 101
Nanobody-enabled monitoring of kappa opioid receptor states
Tao Che, Justin G. English, B. Krumm, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 117
What’s wrong with my experiment?: The impact of hidden variables on neuropsychopharmacology research
Hanna M. Butler-Struben, Amanda C. Kentner, Brian C. Trainor
Neuropsychopharmacology (2022) Vol. 47, Iss. 7, pp. 1285-1291
Open Access | Times Cited: 48
Psychedelic therapy in the treatment of addiction: the past, present and future
Rayyan Zafar, Maxim Siegel, Rebecca Harding, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 37
A µ-opioid receptor modulator that works cooperatively with naloxone
Evan S. O’Brien, Vipin Ashok Rangari, Amal El Daibani, et al.
Nature (2024) Vol. 631, Iss. 8021, pp. 686-693
Closed Access | Times Cited: 14
The role of orexin-1 receptor signaling in demand for the opioid fentanyl
Jennifer E. Fragale, Caroline B. Pantazis, Morgan H. James, et al.
Neuropsychopharmacology (2019) Vol. 44, Iss. 10, pp. 1690-1697
Open Access | Times Cited: 69
Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA
Amanda J. Abraham, Christina M. Andrews, Samantha J. Harris, et al.
Neurotherapeutics (2020) Vol. 17, Iss. 1, pp. 55-69
Open Access | Times Cited: 66
Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
Morgan H. James, Jennifer E. Fragale, R. Nisha Aurora, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 5, pp. 717-719
Open Access | Times Cited: 51
Orexin Reserve: A Mechanistic Framework for the Role of Orexins (Hypocretins) in Addiction
Morgan H. James, Gary Aston‐Jones
Biological Psychiatry (2022) Vol. 92, Iss. 11, pp. 836-844
Open Access | Times Cited: 33
Physiological Role of Orexinergic System for Health
Ines Villano, Marco La Marra, Girolamo Di Maio, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 14, pp. 8353-8353
Open Access | Times Cited: 33
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Fentanyl and Other Opioid Use Disorders: Treatment and Research Needs
Nora D. Volkow, Carlos Blanco
American Journal of Psychiatry (2023) Vol. 180, Iss. 6, pp. 410-417
Closed Access | Times Cited: 18
Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges
Ewa Galaj, Amy Hauck Newman, Zheng‐Xiong Xi
Neuroscience & Biobehavioral Reviews (2020) Vol. 114, pp. 38-52
Open Access | Times Cited: 42
Opioid use disorder and the brain: a clinical perspective
Katherine Herlinger, Anne Lingford‐Hughes
Addiction (2021) Vol. 117, Iss. 2, pp. 495-505
Open Access | Times Cited: 34
Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value
Alessandra Matzeu, Rémi Martin‐Fardon
Frontiers in Behavioral Neuroscience (2022) Vol. 15
Open Access | Times Cited: 26
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Patent review of novel compounds targeting opioid use disorder (2018-2024)
Samuel Obeng, Lance Richard McMahon, Edward Ofori
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Alejandra Pulido-Saavedra, Henrique Nunes Pereira Oliva, Tiago Paiva Prudente, et al.
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets
Kevin Lam, Gary Peltz, Walter K. Kraft
Expert Opinion on Investigational Drugs (2025)
Closed Access
Orexin receptors: possible therapeutic targets for psychiatric disorders
Shigeyuki Chaki
Psychopharmacology (2025)
Closed Access
The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System
Jennifer E. Fragale, Morgan H. James, Jorge A. Avila, et al.
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 117-127
Open Access | Times Cited: 29
Orexin (hypocretin) and addiction
Jacqueline B. Mehr, Michelle M. Bilotti, Morgan H. James
Trends in Neurosciences (2021) Vol. 44, Iss. 11, pp. 852-855
Open Access | Times Cited: 29
A promising chemical series of positive allosteric modulators of the μ-opioid receptor that enhance the antinociceptive efficacy of opioids but not their adverse effects
Kerri D. Pryce, Hye Jin Kang, Farhana Sakloth, et al.
Neuropharmacology (2021) Vol. 195, pp. 108673-108673
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top